Core Viewpoint - Tianyu Co., Ltd. announced the resignation of its Chief Financial Officer, Wang Xiujuan, due to personal reasons, and appointed Wang Chong as the new CFO [1] Group 1 - Wang Xiujuan will no longer hold any position in the company after her resignation [1] - The board of directors approved the appointment of Wang Chong as the new CFO, effective from the date of approval at the 19th meeting of the fifth board of directors [1] - The board also plans to appoint Lu Mengyao as the company's securities affairs representative to assist the board secretary [1]

每经头条（nbdtoutiao）——上市公司净利从暴增9倍到突然预亏超2亿元，董事长为何自掏5000万元补 窟窿？50亿元信托理财也去向成谜，股民直呼看不懂 （记者 王晓波） 每经AI快讯，天宇股份2月13日晚间发布公告称，公司董事会于近日收到公司财务总监王秀娟女士的辞 职报告，王秀娟女士因个人原因辞去公司财务总监职务，辞职后将不再担任公司其他职务，王秀娟女士 离任财务总监职务不会影响公司日常经营活动的有序进行。公司审议通过了《关于聘任公司财务总监的 议案》、《关于聘任公司证券事务代表的议案》。为确保公司财务管理工作的顺利开展，经公司第五届 董事会提名委员会第二次会议、第五届董事会审计委员会第十七次会议审议通过，董事会同意聘任王冲 女士任公司财务总监。公司董事会拟聘任陆梦瑶女士担任公司证券事务代表，协助董事会秘书履行职 责。 ...

浙江天宇药业股份有限公司 关于变更财务总监及聘任证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）于 2026 年 2 月 13 日召开 第五届董事会第十九次会议，审议通过了《关于聘任公司财务总监的议案》、《关 于聘任公司证券事务代表的议案》。现将具体情况公告如下： 一、财务总监离任的情况 公司董事会于近日收到公司财务总监王秀娟女士的辞职报告，王秀娟女士因 个人原因辞去公司财务总监职务，辞职后将不再担任公司其他职务，王秀娟女士 离任财务总监职务不会影响公司日常经营活动的有序进行。根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》及《浙江天宇药业股份有限公司章程》 （以下简称"《公司章程》"）等相关规定，王秀娟女士的辞职报告自送达公司 董事会之日起生效。王秀娟女士原定任期至第五届董事会届满之日止。 截至本公告披露日，王秀娟女士未直接持有公司股份，通过公司 2024 年员 工持股计划间 ...

证券代码：300702 证券简称：天宇股份 公告编号：2026-009 浙江天宇药业股份有限公司 浙江天宇药业股份有限公司（以下简称"公司"）第五届董事会第十九次会 议于 2026 年 2 月 13 日 10：30 以现场结合通讯方式召开，本次会议通知于 2026 年 2 月 13 日以书面、电话、电子邮件方式送达。会议应出席董事 8 名，实际出 席董事 8 名。会议由董事长屠勇军先生主持，公司高级管理人员列席了本次会议。 本次董事会会议的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事就各项议案进行了审议、表决，形成决议如下： 一、审议通过了《关于聘任公司财务总监的议案》。 公司董事会同意聘任王冲女士担任公司财务总监，任期自董事会审议通过之 日起至第五届董事会届满之日止。 第五届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 该事项已经公司董事会提名委员会、审计委员会审议通过。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com. ...

天宇股份2月13日公告，公司董事会于近日收到财务总监王秀娟的辞职报告，王秀娟因个人原因辞去公 司财务总监职务，辞职后将不再担任公司其他职务，辞职报告自送达公司董事会之日起生效。为确保公 司财务管理工作的顺利开展，董事会同意聘任王冲任公司财务总监，任期自公司第五届董事会第十九次 会议审议通过之日起至第五届董事会任期届满之日止。 ...

Core Viewpoint - Tianyu Co., Ltd. focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to deepen its "customer first" strategic goal [1] Group 1: Business Strategy - The company has provided active pharmaceutical ingredients (APIs) for 8 original research drug varieties and aims to add 1-2 new commercialized APIs annually with original research drug companies [1] - The company seeks to strengthen existing partnerships with original research clients while expanding its customer base to enhance its competitive advantage in APIs [1] Group 2: Strategic Partnerships - Tianyu has established long-term stable strategic partnerships with internationally renowned pharmaceutical companies such as Novartis, Sanofi, and Daiichi Sankyo [1] - The scope of cooperation has expanded from sartans APIs to non-sartan APIs, off-patent drugs, and innovative drug CDMO projects, indicating an increase in both depth and breadth of collaboration [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) maintains a stable annual R&D investment of approximately 250-280 million yuan, with a shift in focus towards raw materials and CDMO R&D while decreasing investment in generic drug formulations [1] Group 1: R&D Investment - The company plans to keep its overall R&D investment steady at around 250-280 million yuan each year [1] - There is an increasing proportion of R&D investment allocated to raw materials and CDMO, while the investment in generic drug formulations is gradually declining [1] Group 2: Sales Expenses - The sales expenses for the formulation business are growing rapidly due to its fast development [1] - The company is enhancing its marketing management through the establishment of a digital system [1]

Core Viewpoint - Tianyu Co., Ltd. identifies non-sartan active pharmaceutical ingredients (APIs) such as sitagliptin and ezetimibe as core growth drivers, with expectations for continued rapid growth through 2026 and potential for further gross margin improvement due to economies of scale [1] Group 1 - Non-sartan APIs are expected to be a significant growth driver for the company [1] - The company anticipates maintaining rapid growth in the non-sartan API segment through 2026 [1] - There is potential for further improvement in gross margins as economies of scale become more pronounced [1]

Group 1: R&D and Client Collaboration - The company focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to provide raw materials for 8 original drug varieties and plans to add 1-2 new commercialized raw materials annually [2] - Established long-term strategic partnerships with renowned pharmaceutical companies such as Novartis and Sanofi, expanding collaboration from sartan raw materials to non-sartan raw materials, patent-expired drugs, and innovative drug projects [2] Group 2: CDMO Business Strategy - The company has built a solid service foundation and professional competitiveness in the generic drug raw material field, leveraging a comprehensive GMP system and compliance capabilities [3] - The CDMO business focuses on strategic clients, prioritizing high-potential projects during patent periods and late-stage development, ensuring significant scale benefits and customer loyalty [3] Group 3: Business Growth Outlook for 2026 - Raw material segment: Sartan raw materials' revenue share is expected to decline, while non-sartan raw materials (e.g., sitagliptin, ezetimibe) are projected to be core growth drivers, maintaining rapid growth and potential margin improvement [4] - CDMO business: Revenue may face pressure due to changing client demands, but the company is actively pursuing new project opportunities to maintain stability [4] - Formulation business: Expected to continue rapid growth due to expanding market channels, despite a small revenue base [4] - Acetonitrile project: The annual production capacity of 20,000 tons has passed acceptance in January 2026, targeting high-end fields such as peptides and small nucleic acids [4] Group 4: Profitability and Cost Management - Sartan raw materials maintain a gross margin above 30% despite competitive pricing pressures, with expectations for stable margins as prices stabilize [5] - Non-sartan raw materials' gross margin is expected to improve as production increases and costs decrease, aiming to align closer to sartan products [5] Group 5: R&D and Sales Expenses - The company's overall R&D investment will remain stable at approximately 2.5-2.8 billion annually, with a rising proportion allocated to raw materials and CDMO R&D [5] - Sales expenses are increasing rapidly in the formulation business due to its growth, with the company enhancing marketing control through digital systems [5]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].